Neuropsychopharmacogenetics: 'Stimulating' rationale therapy in attention-deficit/hyperactivity disorder (ADHD): Pharmacogenetics of psychostimulants in ADHD

Psychopharmacogenetics

Volumn , Issue , 2006, Pages 231-248

  Masellis, Mario ^a   Basile, Vincenzo S ^a   Kennedy, James L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651084218     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-34577-2_9     Document Type: Chapter

References (90)

1. American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorder, 4th ed.
2. Anderson, G. M., Cook, E. H., 2000, Pharmacogenetics. Promise and potential in child and adolescent psychiatry, Child Adolesc Psychiatr Clin N Am. 9:23-42.
3. Arranz, M. J., Munro, J., Sham, P., Kirov, G., Murray, R. M., Collier, D. A., Kerwin, R. W., 1998, Metaanalysis of studies on genetic variation in 5-HT2A receptors and clozapine response, Schizophr Res. 32:93-9.
4. Barkley, R. A., McMurray, M. B., Edelbrock, C. S., Robbins, K., 1990, Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation, Pediatrics. 86:184-92.
5. Barr, C. L., Wigg, K. G., Bloom, S., Schachar, R., Tannock, R., Roberts, W., Malone, M., Kennedy, J. L., 2000, Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder, Am J Med Genet. 96:262-7.
6. Basile, V. S., Masellis, M., Badri, F., Paterson, A. D., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Macciardi, F., Kennedy, J. L., 1999, Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia, Neuropsychopharmacology. 21:17-27.
7. Basile, V. S., Ozdemir, V., Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., Kalow, W., Macciardi, F. M., Kennedy, J. L., 2000, A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia, Mol Psychiatry. 5:410-7.
8. Beane, M., Marrocco, R. T., 2004, Norepinephrine and acetylcholine mediation of the components of reflexive attention: implications for attention deficit disorders, Prog Neurobiol. 74:167-81.
9. Billett, E. A., Richter, M. A., King, N., Heils, A., Lesch, K. P., Kennedy, J. L., 1997, Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene, Mol Psychiatry. 2:403-6.
10. Bradley, C., 1937, The behavior of children receiving benzedrine, Am J Psychiatry. 94:577-85.
11. Comings, D. E., Wu, S., Chiu, C., Ring, R. H., Gade, R., Ahn, C., MacMurray, J. P., Dietz, G., Muhleman, D., 1996, Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes-DRD2, D beta H, and DAT1, Am J Med Genet. 67:264-88.
12. Cook, E. H., Jr., 1999, The early development of child psychopharmacogenetics, J Am Acad Child Adolesc Psychiatry. 38:1478-81.
13. Cook, E. H., Jr., Stein, M. A., Krasowski, M. D., Cox, N. J., Olkon, D. M., Kieffer, J. E., Leventhal, B. L., 1995, Association of attention-deficit disorder and the dopamine transporter gene, Am J Hum Genet. 56:993-8.
14. Corman, S. L., Fedutes, B. A., Culley, C. M., 2004, Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder, Am J Health Syst Pharm. 61:2391-9.
15. Crowe, R. R., 1993, Candidate genes in psychiatry: an epidemiological perspective, Am J Med Genet. 48:74-7.
16. Daly, G., Hawi, Z., Fitzgerald, M., Gill, M., 1999, Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children, Mol Psychiatry. 4:192-6.
17. DeVane, C. L., Markowitz, J. S., Carson, S. W., Boulton, D. W., Gill, H. S., Nahas, Z., Risch, S. C., 2000, Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers, J Clin Psychopharmacol. 20:347-9.
18. Elia, J., Borcherding, B. G., Rapoport, J. L., Keysor, C. S., 1991, Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?, Psychiatry Res. 36:141-55.
19. Evans, W. E., McLeod, H. L., 2003, Pharmacogenomics-drug disposition, drug targets, and side effects, N Engl J Med. 348:538-49.
20. Faraone, S. V., Biederman, J., 1994, Genetics of ADHD, Child Adolesc Psychiatr Clin North America. 3:285-301
21. Faraone, S. V., Biederman, J., Spencer, T., Wilens, T., Seidman, L. J., Mick, E., Doyle, A. E., 2000, Attention-deficit/hyperactivity disorder in adults: an overview, Biol Psychiatry. 48:9-20.
22. Frazier, T. W., Demaree, H. A., Youngstrom, E. A., 2004, Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/ hyperactivity disorder, Neuropsychology. 18:543-55.
23. Fuke, S., Suo, S., Takahashi, N., Koike, H., Sasagawa, N., Ishiura, S., 2001, The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression, Pharmacogenomics J. 1:152-6.
24. Gill, M., Daly, G., Heron, S., Hawi, Z., Fitzgerald, M., 1997, Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism, Mol Psychiatry. 2:311-3.
25. Gillis, J. J., Gilger, J. W., Pennington, B. F., DeFries, J. C., 1992, Attention deficit disorder in readingdisabled twins: evidence for a genetic etiology, J Abnorm Child Psychol. 20:303-15.
26. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., Caron, M. G., 1996, Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter, Nature. 379:606-12.
27. Gottesman, I. I., 1991, Schizophrenia Genesis. The Origins of Madness, W. H. Freeman and Company, New York
28. Greenblatt, D. J., Harmatz, J. S., Von Moltke, L. L., Shader, R. I. (1995). Pharmacokinetics and Pharmaco-dynamics. In Psychopharmacology: The Fourth Generatiion of Progress, ed. Bloom, F. E., Kupfer, D. J., pp. 849-58. New York: Raven Press.
29. Greenhill, L. L., Pliszka, S., Dulcan, M. K., Bernet, W., Arnold, V., Beitchman, J., Benson, R. S., Bukstein, O., Kinlan, J., McClellan, J., Rue, D., Shaw, J. A., Stock, S., 2002, Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults, J Am Acad Child Adolesc Psychiatry. 41:26S-49S.
30. Hechtman, L., 1994, Genetic and neurobiological aspects of attention deficit hyperactive disorder: a review, J Psychiatry Neurosci. 19:193-201.
31. Hervey, A. S., Epstein, J. N., Curry, J. F., 2004, Neuropsychology of adults with attentiondeficit/hyperactivity disorder: a meta-analytic review, Neuropsychology. 18:485-503.
32. Hubbard, J. W., Srinivas, N. R., Quinn, D., Midha, K. K., 1989, Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder, J Pharm Sci. 78:944-7.
33. Kalow, W., Tang, B. K., Endrenyi, L., 1998, Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research, Pharmacogenetics. 8:283-9.
34. Kane, J. M., Smith, J. M., 1982, Tardive dyskinesia: prevalence and risk factors, 1959 to 1979, Arch Gen Psychiatry. 39:473-81.
35. Kelly, K. L., Rapport, M. D., DuPaul, G. J., 1988, Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning, Int Clin Psychopharmacol. 3:167-81.
36. Kimko, H. C., Cross, J. T., Abernethy, D. R., 1999, Pharmacokinetics and clinical effectiveness of methylphenidate, Clin Pharmacokinet. 37:457-70.
37. Kirley, A., Lowe, N., Hawi, Z., Mullins, C., Daly, G., Waldman, I., McCarron, M., O'Donnell, D., Fitzgerald, M., Gill, M., 2003, Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD, Am J Med Genet B Neuropsychiatr Genet. 121:50-4.
38. Krause, K. H., Dresel, S. H., Krause, J., Kung, H. F., Tatsch, K., 2000, Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography, Neurosci Lett. 285:107-10.
39. LaHoste, G. J., Swanson, J. M., Wigal, S. B., Glabe, C., Wigal, T., King, N., Kennedy, J. L., 1996, Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder [see comments], Mol Psychiatry. 1:121-4.
40. Leboyer, M., Bellivier, F., Nosten-Bertrand, M., Jouvent, R., Pauls, D., Mallet, J., 1998, Psychiatric genetics: search for phenotypes, Trends Neurosci. 21:102-5.
41. Levin, E. D., Conners, C. K., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., Rose, J. E., March, J., 1996, Nicotine effects on adults with attention-deficit/hyperactivity disorder, Psychopharmacology (Berl). 123:55-63.
42. Loo, S. K., Hopfer, C., Teale, P. D., Reite, M. L., 2004, EEG Correlates of Methylphenidate Response in ADHD: Association With Cognitive and Behavioral Measures, J Clin Neurophysiol. 21:457-64.
43. Loo, S. K., Specter, E., Smolen, A., Hopfer, C., Teale, P. D., Reite, M. L., 2003, Functional effects of the DAT1 polymorphism on EEG measures in ADHD, J Am Acad Child Adolesc Psychiatry. 42:986-93.
44. Lott, D. C., Kim, S. J., Cook, E. H., De Wit, H., 2004, Dopamine Transporter Gene Associated with Diminished Subjective Response to Amphetamine, Neuropsychopharmacology.
45. Malhotra, A. K., Goldman, D., 1999, Benefits and pitfalls encountered in psychiatric genetic association studies, Biol Psychiatry. 45:544-50.
46. Markowitz, J. S., Patrick, K. S., 2001, Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder, Clin Pharmacokinet. 40:753-72.
47. Masellis, M., Basile, V., Meltzer, H. Y., Lieberman, J. A., Sevy, S., Macciardi, F. M., Cola, P., Howard, A., Badri, F., Nothen, M. M., Kalow, W., Kennedy, J. L., 1998, Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients, Neuropsychopharmacology. 19:123-32.
48. Masellis, M., Basile, V. S., Meltzer, H. Y., Lieberman, J. A., Sevy, S., Goldman, D. A., Hamblin, M. W., Macciardi, F. M., Kennedy, J. L., 2001, Lack of association between the T/C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia., Schizophrenia Research. 47:49-58.
49. Masellis, M., Basile, V. S., Ozdemir, V., Meltzer, H. Y., Macciardi, F. M., Kennedy, J. L., 2000, Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine, Biol Psychiatry. 47:252-66.
50. Masellis, M., Paterson, A. D., Badri, F., Lieberman, J. A., Meltzer, H. Y., Cavazzoni, P., Kennedy, J. L., 1995, Genetic variation of 5-HT2A receptor and response to clozapine, Lancet. 346:1108.
51. Mill, J., Asherson, P., Browes, C., D'Souza, U., Craig, I., 2002, Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR, Am J Med Genet. 114:975-9.
52. Mollica, C. M., Maruff, P., Vance, A., 2004, Development of a statistical approach to classifying treatment response in individual children with ADHD, Hum Psychopharmacol. 19:445-56.
53. Muglia, P., Jain, U., Macciardi, F., Kennedy, J. L., 2000, Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene, Am J Med Genet. 96:273-7.
54. Nigg, J. T., Blaskey, L. G., Stawicki, J. A., Sachek, J., 2004, Evaluating the endophenotype model of ADHD neuropsychological deficit: results for parents and siblings of children with ADHD combined and inattentive subtypes, J Abnorm Psychol. 113:614-25.
55. NIH, 1998a, Mechanisms underlying variations in drug responses, www.nih.gov/grants/guide/pa-files/PA-99-016.html pps. 1-10.
56. NIH, 1998b, Pharmacogenetics research network and database, www.nih.gov/grants/guide/rfa-files/RFA-GM-099-004.html pps. 1-18.
57. Nurnberger, J. I., Jr., Gershon, E. S., Simmons, S., Ebert, M., Kessler, L. R., Dibble, E. D., Jimerson, S. S., Brown, G. M., Gold, P., Jimerson, D. C., Guroff, J. J., Storch, F. I., 1982, Behavioral, biochemical and neuroendocrine responses to amphetamine in normal twins and 'well-state' bipolar patients, Psychoneuroendocrinology. 7:163-76.
58. Ozdag, M. F., Yorbik, O., Ulas, U. H., Hamamcioglu, K., Vural, O., 2004, Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder, Int J Pediatr Otorhinolaryngol. 68:1267-72.
59. Pauls, D. L., 1991, Genetic factors in the expression of attention-deficit hyperactivity disorder, J Child Adolesc Psychopharm. 1:353-60.
60. Rietschel, M., Kennedy, J. L., Macciardi, F. M., DeLisi, L., Meltzer, H. Y., The Consensus Group for Outcome Measures in Psychoses for Pharmacogenetic Studies, 1999, Pharmacogenetics in psychosis, the first consensus conference, Schizophrenia Research. 37:191-6.
61. Rohde, L. A., Roman, T., Szobot, C., Cunha, R. D., Hutz, M. H., Biederman, J., 2003, Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attentiondeficit/hyperactivity disorder: a pilot study, Synapse. 48:87-9.
62. Roman, T., Szobot, C., Martins, S., Biederman, J., Rohde, L. A., Hutz, M. H., 2002, Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder, Pharmacogenetics. 12:497-9.
63. Rowe, D. C., Stever, C., Giedinghagen, L. N., Gard, J. M., Cleveland, H. H., Terris, S. T., Mohr, J. H., Sherman, S., Abramowitz, A., Waldman, I. D., 1998, Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder, Mol Psychiatry. 3:419-26.
64. Rowland, M., Tozer, T. N., 1995, Clinical Pharmacokinetics. Concepts and Applications, Williams & Wilkins, Philadelphia.
65. Safer, D. J., Krager, J. M., 1988, A survey of medication treatment for hyperactive/inattentive students, Jama. 260:2256-8.
66. Seeman, P., Madras, B. K., 1998, Anti-hyperactivity medication: methylphenidate and amphetamine, Mol Psychiatry. 3:386-96.
67. Seidman, L. J., Biederman, J., Monuteaux, M. C., Weber, W., Faraone, S. V., 2000, Neuropsychological functioning in nonreferred siblings of children with attention deficit/hyperactivity disorder, J Abnorm Psychol. 109:252-65.
68. Shafritz, K. M., Marchione, K. E., Gore, J. C., Shaywitz, S. E., Shaywitz, B. A., 2004, The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder, Am J Psychiatry. 161:1990-7.
69. Shaywitz, S. E., Hunt, R. D., Jatlow, P., Cohen, D. J., Young, J. G., Pierce, R. N., Anderson, G. M., Shaywitz, B. A., 1982, Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate, Pediatrics. 69:688-94.
70. Shytle, R. D., Silver, A. A., Wilkinson, B. J., Sanberg, P. R., 2002, A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder, World J Biol Psychiatry. 3:150-5.
71. Slaats-Willemse, D., Swaab-Barneveld, H., De Sonneville, L., Van Der Meulen, E., Buitelaar, J., 2003, Deficient response inhibition as a cognitive endophenotype of ADHD, J Am Acad Child Adolesc Psychiatry. 42:1242-8.
72. Smeraldi, E., Zanardi, R., Benedetti, F., Di Bella, D., Perez, J., Catalano, M., 1998, Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine, Mol Psychiatry. 3:508-11.
73. Solanto, M. V., 1998, Neuropsychopharmacological mechanisms of stimulant drug action in attentiondeficit hyperactivity disorder: a review and integration, Behav Brain Res. 94:127-52.
74. Srinivas, N. R., Hubbard, J. W., Korchinski, E. D., Midha, K. K., 1993, Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans, Pharm Res. 10:14-21.
75. Srinivas, N. R., Hubbard, J. W., Quinn, D., Midha, K. K., 1992, Enantioselective pharmacokinetics and pharmacodynamics of dl-threo- methylphenidate in children with attention deficit hyperactivity disorder, Clin Pharmacol Ther. 52:561-8.
76. Stein, M. A., Sarampote, C., Waldman, I., Seymour, K., Robb, A., Colon, C., et al., 2002, Dopamine transporter genotype affects stimulant response according to parent ratings. Presented at 49th Annual Meeting of Child and Adolescent Psychiatry, San Francisco.
77. Sun, Z., Murry, D. J., Sanghani, S. P., Davis, W. I., Kedishvili, N. Y., Zou, Q., Hurley, T. D., Bosron, W. F., 2004, Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1, J Pharmacol Exp Ther. 310:469-76.
78. Sunohara, G. A., Roberts, W., Malone, M., Schachar, R. J., Tannock, R., Basile, V. S., Wigal, T., Wigal, S. B., Schuck, S., Moriarty, J., Swanson, J. M., Kennedy, J. L., Barr, C. L., 2000, Linkage of the dopamine D4 receptor gene and attention-deficit/hyperactivity disorder, J Am Acad Child Adolesc Psychiatry. 39:1537-42.
79. Swanson, J. M., Sunohara, G. A., Kennedy, J. L., Regino, R., Fineberg, E., Wigal, T., Lerner, M., Williams, L., LaHoste, G. J., Wigal, S., 1998, Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach, Mol Psychiatry. 3:38-41.
80. Swerdlow, N. R., Shoemaker, J. M., Platten, A., Pitcher, L., Goins, J., Crain, S., 2003, Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rat strains, Pharmacol Biochem Behav. 75:191-7.
81. Tahir, E., Yazgan, Y., Cirakoglu, B., Ozbay, F., Waldman, I., Asherson, P. J., 2000, Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children, Mol Psychiatry. 5:396-404.
82. Thomson, G., 1995, Mapping disease genes: family-based association studies, American Journal of Human Genetics. 57:487-98.
83. Ujike, H., Harano, M., Inada, T., Yamada, M., Komiyama, T., Sekine, Y., Sora, I., Iyo, M., Katsu, T., Nomura, A., Nakata, K., Ozaki, N., 2003, Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis, Pharmacogenomics J. 3:242-7.
84. Waldman, I. D., Rowe, D. C., Abramowitz, A., Kozel, S. T., Mohr, J. H., Sherman, S. L., Cleveland, H. H., Sanders, M. L., Gard, J. M., Stever, C., 1998, Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity, Am J Hum Genet. 63:1767-76.
85. Westerberg, H., Hirvikoski, T., Forssberg, H., Klingberg, T., 2004, Visuo-spatial working memory span: a sensitive measure of cognitive deficits in children with ADHD, Neuropsychol Dev Cogn C Child Neuropsychol. 10:155-61.
86. Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., Polisner, D., 1999, A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder, Am J Psychiatry. 156:1931-7.
87. Wilens, T. E., Biederman, J., Wong, J., Spencer, T. J., Prince, J. B., 2000, Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series, J Child Adolesc Psychopharmacol. 10:217-22.
88. Winsberg, B. G., Comings, D. E., 1999, Association of the dopamine transporter gene (DAT1) with poor methylphenidate response, J Am Acad Child Adolesc Psychiatry. 38:1474-7.
89. Yang, L., Wang, Y. F., Li, J., Faraone, S. V., 2004, Association of norepinephrine transporter gene with methylphenidate response, J Am Acad Child Adolesc Psychiatry. 43:1154-8.
90. Yang, P. B., Amini, B., Swann, A. C., Dafny, N., 2003, Strain differences in the behavioral responses of male rats to chronically administered methylphenidate, Brain Res. 971:139-52.